# Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC

> **NCT02999646** · NA · COMPLETED · sponsor: **Maxivax SA** · enrollment: 16 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **OTHER:** MVX-ONCO-1

## Key facts

- **NCT ID:** NCT02999646
- **Lead sponsor:** Maxivax SA
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-25
- **Primary completion:** 2023-01-25
- **Final completion:** 2023-06-29
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02999646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02999646, "Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02999646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*